| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H32ClN3O4.ClH |
| Molecular Weight | 558.496 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC[C@@]1(O)CC(=O)OCC2=C1C=C3N(CC4=C3N=C5C=C(Cl)C(C)=CC5=C4CN6CCC(C)CC6)C2=O
InChI
InChIKey=OLYFGLXPXPABOP-XXIQNXCHSA-N
InChI=1S/C29H32ClN3O4.ClH/c1-4-29(36)12-26(34)37-15-21-22(29)10-25-27-20(14-33(25)28(21)35)19(13-32-7-5-16(2)6-8-32)18-9-17(3)23(30)11-24(18)31-27;/h9-11,16,36H,4-8,12-15H2,1-3H3;1H/t29-;/m1./s1
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Phase I study. Elomotecan was administered as a 30-min intravenous infusion at doses ranging from 1.5 to 75 mg once every 3 weeks to 56 patients with advanced solid tumors. Plasma concentration data and adverse effects were modeled using the population approach.
Route of Administration:
Intravenous
The antiproliferative activity of elomotecan (BN 80927) was determined on various human tumor cell lines from a diverse set of target organs, including leukemia and solid tumors (colon, prostate, ovary, lung, bladder, and breast cell lines). BN80927 was an antiproliferative agent on all of the cell lines tested. On this set of cell lines, BN80927 has IC50 values 2–81 nM.
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
